Status:
COMPLETED
Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT
Lead Sponsor:
Sir Salimullah Medical College Mitford Hospital
Conditions:
Non-Alcoholic Fatty Liver Disease
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This study will be conducted upon the patients with fatty liver disease. Patients who will be diagnosed as a case of fatty liver disease by ultrasound with raised liver enzyme (ALT) will be primarily ...
Detailed Description
Non-alcoholic fatty liver disease (NAFLD) is an increasingly common cause of chronic liver disease worldwide and it is associated with increased liver-related mortality and hepatocellular carcinoma, e...
Eligibility Criteria
Inclusion
- NAFLD (by USG)
- Raised ALT (\>40 U/L)
Exclusion
- Patient with significant alcohol intake (more than 20 gm/day).
- Patient with history of taking drugs that may cause fatty liver (i.e. tamoxifen, valproic acid, amiodarone, methotrexate, steroid, OCP) or history of taking drugs that have shown benefit in previous NASH pilot studies (i.e. vitamin E, metformin, thiazolidinediones, statin, ARB, fibrates, DPP-4 inhibitor, Omega-3 fatty acid).
- Chronic viral hepatitis (HBV, HCV).
- Pregnancy
- Patient with co-morbid condition (COPD, CKD, CCF etc.)
- Patient with history of recent MI
- Patient with liver failure
- Patient with hypothyroidism
Key Trial Info
Start Date :
March 5 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT03836937
Start Date
March 5 2019
End Date
December 31 2021
Last Update
May 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hepatology
Dhaka, Bangladesh, 1000